Nektar Therapeutics (NKTR) EBIT Growth (3y) (2013 - 2026)
Powered by 
Analysis
Nektar Therapeutics (NKTR) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -18.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.27% |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | 5.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.77% |
| Mar 31, 2026 | 33.82% |
| Dec 31, 2025 | 19.21% |
| Sep 30, 2025 | 16.45% |
| Jun 30, 2025 | 38.11% |
| Mar 31, 2025 | 27.44% |
| Dec 31, 2024 | 28.61% |
| Sep 30, 2024 | 32.88% |
| Jun 30, 2024 | 23.28% |
| Mar 31, 2024 | 31.33% |
| Dec 31, 2023 | 32.86% |
| Sep 30, 2023 | 24.21% |
| Jun 30, 2023 | 13.33% |
| Mar 31, 2023 | -0.27% |
| Dec 31, 2022 | 21.78% |
| Sep 30, 2022 | 18.07% |
| Jun 30, 2022 | -11.26% |
| Mar 31, 2022 | 1.15% |
| Dec 31, 2021 | -4.03% |
| Sep 30, 2021 | -4.82% |